More than 1.1 million seniors in the Medicare program could die prematurely over the next decade because they cannot afford the exorbitant prices of prescription medications.\r\n\r\n\u0022High prescription drug prices cost lives. Period.\u0022\r\n—David Mitchell, Patients For Affordable Drugs Now\r\n\r\nThat\u0026#039;s according to a\u0026nbsp;study\u0026nbsp;released last week by the West Health Policy Center, a nonprofit and nonpartisan policy research group, and Xcenda, the research arm of AmerisourceBergen, a drug distributor.\r\n\r\nResearchers expect \u0022cost-related nonadherence\u0022 to drug therapy to increase not only\u0026nbsp;unnecessary suffering but\u0026nbsp;also Medicare spending, as deteriorating health conditions drive up preventable expenses by more than $177 billion by 2030.\u0026nbsp;\r\n\r\nUnless drug prices are reduced, the analysis estimated that 112,000 seniors per year could succumb to early death as a result of not being able to afford their medications. In addition, researchers projected that health complications stemming from the unaffordable cost of prescriptions will force Medicare to spend nearly $18 billion annually on avoidable medical expenses.\r\n\r\n\r\n\r\nHigh prescription drug prices cost lives. Period.\r\nPowerful new study from @WestHealth.\r\nDrugs don\u0026#039;t work if people can\u0026#039;t afford them.\r\nMust restore balance to get innovation we need at prices we can afford. End unlimited drug corporation pricing power. https://t.co/N4NLvga0af\r\n— David Mitchell (@DavidP4AD) November 20, 2020\r\n\r\n\r\nPrescription drug prices have been\u0026nbsp;soaring, with list prices having increased by 159% from 2007 to 2018.\u0026nbsp;\r\n\r\nWest Health noted that if these trends continue, cost-related nonadherence to drug therapy will be \u0022a leading cause of death in the U.S., ahead of diabetes, influenza, pneumonia, and kidney disease.\u0022\r\n\r\n\u0022One of the biggest contributors to poor health, hospital admissions, higher healthcare costs, and preventable death is patients failing to take their medications as prescribed,\u0022 said Timothy Lash, president of the West Health Policy Center. \u0022Cost-related nonadherence is a significant and growing issue that is a direct result of runaway drug prices and a failure to implement policies and regulations that make drugs more affordable.\u0022\r\n\r\nThe good news is that policy changes can curb the power of Big Pharma, resulting in far fewer avoidable deaths.\r\n\r\nCurrently, Medicare beneficiaries are required to pay 25% of the list price cost of generic and brand-name medications until they reach their out-of-pocket maximum.\r\n\r\n\u0022As drug companies continue to raise list prices,\u0022 the analysis\u0026nbsp;explained, \u0022patients may experience a significant increase in their coinsurance costs.\u0022\u0026nbsp;\r\n\r\nIf Medicare were able to directly negotiate with pharmaceutical companies—as described in H.R. 3,\u0026nbsp;The Elijah Cummings Lower Drug Costs Now Act, which has languished on the desk of Senate Majority Leader Micth McConnell (R-Ky.) since it was passed by House Democrats in December 2019—it would result in dramatically lower prescription drug prices nationwide.\u0026nbsp;\r\n\r\nH.R. 3 is backed by the Patients For Affordable Drugs Now coalition. David Mitchell, a cancer patient and the founder of the group, said last year that the legislative proposal could \u0022help fix our broken system and ensure Americans with private and public insurance get the drugs they need at lower prices.\u0022\r\n\r\n\r\n\r\nAs patients skip doses, ration medication or quit treatment all together--medical conditions will worsen and cost Medicare an extra $177.4 billion over the next 10 years. https://t.co/cOeYxdFL9o pic.twitter.com/BzvWBGg5tu\r\n— West Health (@WestHealth) November 19, 2020\r\n\r\n\r\nAccording to\u0026nbsp;the Council for Informed Drug Spending Analysis (CIDSA), allowing Medicare to negotiate and limit drug price increases could prevent nearly 94,000 deaths per year while also reducing Medicare spending by almost $476 billion by 2030.\r\n\r\nSean Dickson, director of health policy at West Health Policy Center and chair of CIDSA,\u0026nbsp;said that \u0022the costs of doing nothing about high drug prices are too high.\u0022\r\n\r\n\u0022Especially when policy changes such as allowing Medicare to negotiate drug prices would result in saving millions of lives and billions of dollars,\u0022 he added.